RT Journal Article
SR Electronic
T1 Advancing precision care in pregnancy through an actionable fetal findings list
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.26.24314442
DO 10.1101/2024.09.26.24314442
A1 Cohen, Jennifer L.
A1 Duyzend, Michael
A1 Adelson, Sophia M.
A1 Yeo, Julie
A1 Fleming, Mark
A1 Ganetzky, Rebecca
A1 Hale, Rebecca
A1 Mitchell, Deborah M.
A1 Morton, Sarah U.
A1 Reimers, Rebecca
A1 Roberts, Amy
A1 Strong, Alanna
A1 Tan, Weizhen
A1 Thiagarajah, Jay R.
A1 Walker, Melissa A.
A1 Green, Robert C.
A1 Gold, Nina B.
YR 2024
UL http://medrxiv.org/content/early/2024/09/30/2024.09.26.24314442.abstract
AB The use of genomic sequencing (GS) for prenatal diagnosis of fetuses with sonographic abnormalities has grown tremendously over the past decade. Fetal GS also offers an opportunity to identify incidental genomic variants that are unrelated to the fetal phenotype, but may be relevant to fetal and newborn health. There are currently no guidelines for reporting incidental findings from fetal GS.In the United States, GS for adults and children is recommended to include a list of “secondary findings” genes (ACMG SF v3.2) that are associated with disorders for which surveillance or treatment can reduce morbidity and mortality. The genes on ACMG SF v3.2 predominantly cause adult-onset disorders. Importantly, many genetic disorders with fetal and infantile onset are actionable as well.A proposed solution is to create a “fetal actionable findings list,” which can be offered to pregnant patients undergoing fetal GS or eventually, as a standalone cell-free fetal DNA screening test. In this integrative review, we propose criteria for an actionable fetal findings list, then identify genetic disorders with clinically available or emerging fetal therapies, and those for which clinical detection in the first week of life might lead to improved outcomes. Finally, we synthesize the potential benefits, limitations, and risks of an actionable fetal findings list.Competing Interest StatementJennifer Cohen receives compensation for advising at Bayer HealthCare Pharmaceuticals and serves as an advisor on a Sanofi Advisory Board. Michael Duyzend has received a speaking honorarium from Illumina, Inc. Mark Fleming has received compensation for advising the following companies: Vertex Pharmaceuticals, Affyimmune Pharmaceuticals, and Evolve Immune Pharmaceuticals. He also serves on scientific advisory boards for Disc Medicine and Minerva Biotechnologies. Rebecca Ganetzky is a paid consultant for Nurture Genomics & Minovia Therapeutics. Deborah Mitchell receives compensation for advising the following companies: Amolyt, Ascendis. Weizhen Tan serves as a paid consultant for Amgen Pharmaceuticals and participates on an Advisory Board for cystinosis. Melissa Walker is an author on pending patent application U.S. Provisional Patent Application, 63/034,740 "Methods of Detecting Mitochondrial Diseases". Robert Green has received compensation for advising the following companies: Allelica, Atria, Fabric and Juniper Genomics; and is a co-founder of Genome Medical and Nurture Genomics. Nina Gold has received an honorarium from Ambry Genetics.Funding StatementThis work was supported by the following grants: K23HD113824-01A1 (J.L.C), F32HD112084 (M.D.), T32A1007512 (R.H.), R01DK122581 (D.M.M), AHA Career Development Award (S.U.M.), NIH 1K08HL157653 (S.U.M.), KL2TR002552 (R.R.), K08DK128606 (A.S.), RC2DK118640 (J.R.T.), RC2DK122532 (J.R.T.), K08NS117889 (M.A.W.), HD077671 (R.C.G.), TR003201 (R.C.G.), K08HG012811 (N.B.G.), U01TR003201 (N.B.G.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.